Fate Therapeutics, Inc. (FATE)

5.39 +0.16 (+3.06%) At close: 04:00PM EDT

Fate Therapeutics, Inc.

12278 Scripps Summit Drive
San Diego, CA 92131
United States
858 875 1800
https://www.fatetherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 551

Key executives

Name	Title	Pay	Exercised	Year born
Mr. J. Scott Wolchko	Founder, CEO, Pres & Director	976k	25.12M	1970
Mr. Edward J. Dulac III	Chief Financial Officer	588k	821.37k	1976
Ms. Cindy R. Tahl	Gen. Counsel & Corp. Sec.	602k	13.37M	1973
Dr. Bahram Valamehr Ph.D.	Chief R&D Officer	602k	7.11M	1977
Dr. Yu-Waye Chu M.D.	Chief Medical Officer	602k	263.51k	N/A
Mr. Jim Beitel M.B.A.	Sr. VP of Corp. Devel.	N/A	N/A	N/A
Dr. Sarah Cooley	Sr. VP of Clinical Translation	N/A	N/A	N/A
Dr. Jerome Bressi Ph.D.	Sr. VP of Regulatory & Quality	N/A	N/A	N/A
Mr. Brian T. Powl M.B.A., M.S.	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Corporate governance

Fate Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2023 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.